Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.67 |
| ▸ | F10 | P00742 | 3/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.60 |
| ▸ | NQO2 | P16083 | 2/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.52 |
| ▸ | PROC | P04070 | 1/20 | 0.52 |
| ▸ | HPN | P05981 | 1/20 | 0.52 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.52 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.52 |
| ▸ | KLK1 | P06870 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905557 | 0.94 | F2 (0.61) | F2F10PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL7417746 | 0.88 | F2 (0.67) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL8109478 | 0.87 | F2 (0.68) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6141244 | 0.84 | F2 (0.64) | F2F10PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL7412015 | 0.84 | F2 (0.62) | F2F10PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL7411415 | 0.83 | F2 (0.62) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL3001133 | 0.82 | F2 (0.80) | F2F10PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL7101701 | 0.81 | F2 (0.79) | F2F10PRSS1PRSS2PRSS3 | |
| Tanogitran SCHEMBL29456575 | 0.80 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| Tanogitran SCHEMBL2989514 | 0.80 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076934-A1 | (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1- (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition | LINZ GUENTER | 2008-03-27 | — | — | US | disclosed |
| US-20040010026-A1 | (R) 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1 (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076934-A1 | (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1- (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition | PBRM1, H1-4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | F2 1369/4885F10 3269/4885PRSS1 3677/4885 |
| US-20040010026-A1 | (R) 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1 (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition | PBRM1, H1-4, PKD1 | F2 1545/4885F10 3756/4885PRSS1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.